83 related articles for article (PubMed ID: 25524406)
21. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
22. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
[TBL] [Abstract][Full Text] [Related]
23. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
24. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
25. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.
Li QX; Mok SS; Laughton KM; McLean CA; Cappai R; Masters CL; Culvenor JG; Horne MK
Exp Neurol; 2007 Apr; 204(2):583-8. PubMed ID: 17258710
[TBL] [Abstract][Full Text] [Related]
26. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
27. Decreased plasma levels of neureglin-1 in drug naïve patients and chronic patients with schizophrenia.
Wang R; Wang Y; Hu R; Chen X; Song M; Wang X
Neurosci Lett; 2015 Oct; 606():220-4. PubMed ID: 26365407
[TBL] [Abstract][Full Text] [Related]
28. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
29. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
[TBL] [Abstract][Full Text] [Related]
30. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis.
Licker V; Turck N; Kövari E; Burkhardt K; Côte M; Surini-Demiri M; Lobrinus JA; Sanchez JC; Burkhard PR
Proteomics; 2014 Mar; 14(6):784-94. PubMed ID: 24449343
[TBL] [Abstract][Full Text] [Related]
31. Neuregulin 1/ErbB4 enhances synchronized oscillations of prefrontal cortex neurons via inhibitory synapses.
Hou XJ; Ni KM; Yang JM; Li XM
Neuroscience; 2014 Mar; 261():107-17. PubMed ID: 24374327
[TBL] [Abstract][Full Text] [Related]
32. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses.
Hofstee DJ; Neef C; van Laar T; Jansen EN
Clin Neuropharmacol; 1994 Feb; 17(1):45-52. PubMed ID: 8149359
[TBL] [Abstract][Full Text] [Related]
34. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K
Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021
[TBL] [Abstract][Full Text] [Related]
35. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
Hall H; Reyes S; Landeck N; Bye C; Leanza G; Double K; Thompson L; Halliday G; Kirik D
Brain; 2014 Sep; 137(Pt 9):2493-508. PubMed ID: 25062696
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1.
Rösler TW; Depboylu C; Arias-Carrión O; Wozny W; Carlsson T; Höllerhage M; Oertel WH; Schrattenholz A; Höglinger GU
Neuropharmacology; 2011 Dec; 61(8):1413-8. PubMed ID: 21903113
[TBL] [Abstract][Full Text] [Related]
37. Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease.
Gao L; Díaz-Corrales FJ; Carrillo F; Díaz-Martín J; Caceres-Redondo MT; Carballo M; Palomino A; López-Barneo J; Mir P
Acta Neurol Scand; 2010 Jul; 122(1):41-5. PubMed ID: 20085561
[TBL] [Abstract][Full Text] [Related]
38. Neuregulin 1-β regulates cell adhesion molecule L1 expression in the cortex and hippocampus of mice.
Liu Y; Yu Y; Schachner M; Zhao W
Biochem Biophys Res Commun; 2013 Nov; 441(1):7-12. PubMed ID: 24140408
[TBL] [Abstract][Full Text] [Related]
39. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
[TBL] [Abstract][Full Text] [Related]
40. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
